Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib versus osimertinib or lazertinib in first-line EGFR-mutated advanced non-small cell lung cancer
MOH_2020-08-21_009247Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + lazertinib, Osimertinib + placebo and Lazertinib + placebo (3 arms). Primary endpoint: Progression-free survival. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-08-21_009247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-21_009247.